Skip to main content Skip to footer

Precision Medicine

Our comprehensive survey of 1800 people in the US

Health and Life Sciences Experience Survey 2021

Precision medicine for better patient outcomes

Our cell and gene expertise


Working with clients in all three commercially approved CGT therapies.


Active clients in CGT globally.


We are helping clients across three areas: R&D, supply chain and patient engagement.

CAR-T cell therapy: Meet Emily Whitehead

Together through data collaboratives


Enabling next-gen Cell & Gene Therapies

The potential of precision medicine


For the most expensive precision medicine today.1


New cancer drugs are currently in late-stage development, and over 90% of these are targeted therapies.2


Increase in the number of active agents in the global immuno-oncology pipeline.3

What we do

Growth services

Bringing our deep precision medicine expertise to help clients design and build drug development for shifting manufacturing and commercial operations.

Experience and service strategy and design

Shaping and designing industry-leading patient and healthcare professional experiences and services with our business service design arm Fjord.

Advanced analytics

Leveraging our data science expertise: accelerate R&D, enable clinically relevant biomarkers, action patient care analytics along their lifespan.

Data and platform strategies

Aggregating, analyzing and actioning patient data and insight from across their healthcare and everyday experience using architectures and platforms, including INTIENT.

Accelerating the culture cure

Advancements in cell and gene therapy

What we think

The experience report – Cancer patient issue

The Cancer Patient Issue takes a human-centered approach—this time to uncover the main pain points for cancer patients.

Biopharma’s golden opportunity

A differentiated engagement is about understanding the needs of oncologists to better support them and doing so offers significant value to biopharma.

New Science: A new economic reality for growth

As New Science grows in prominence, a new economic environment is demanding change for biopharma’s. 

Gene therapy gets personal

Accenture helped a biopharma company implement a patient-centered platform to manage the delivery of a personalized gene therapy solution.

Roche NAVIFY® Tumor Board: improving cancer care

With data integration provided by Accenture, Roche's NAVIFY® Tumor Board is changing the way tumor board meetings are organized and conducted.

Speeding an innovative cell therapy to market

A biopharmaceutical company collaborates with Accenture to navigate a complex FDA submission for an innovative cell therapy.


Voices of Life Sciences

Our leaders

Stuart Henderson

Market Unit Lead – US Northeast

Andrea Brückner

Managing Director, EU Lead – Life Sciences

Dr. André T. Dahinden

Managing Director – Life Sciences, Precision Oncology and PHC, Global

Sanjay Srivastava, Ph.D

Managing Director – Life Sciences, Cell and Gene Lead


New Science

A dynamic combination of the best in science and health technology is filling unmet needs with more precise and effective treatments.


A platform that enables insights and collaboration across the life sciences enterprise.

Cloud first for Life Sciences

Finding new ways to unlock data, improve engagement and transform your business with cloud.

Frequently asked questions